MicroRNA-22-3p targeted regulating transcription factor 7-like 2 (TCF7L2) constrains the Wnt/β-catenin pathway and malignant behavior in osteosarcoma

References

• Ritter J, Bielack S. Osteosarcoma. Ann Oncol. 2010;21:vii320’5.
   PubMed Web of Science ®Google Scholar
• Corre I, Verrecchia F, Crenn V, et al. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 2020;9(4):976.
   Web of Science ®Google Scholar
• Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2017;13(4):357’368.
   PubMed Web of Science ®Google Scholar
• Karadurmus N, Sahin U, Bahadir Basgoz B, et al. Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing’s sarcoma and osteosarcomas? Journal of B.U.ON.: official journal of the Balkan Union of Oncology. 2018;23(5): 1235’1241
   PubMed Web of Science ®Google Scholar
• Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: a Review of Current and Future Strategies. Int J Mol Sci. 2020;21(18).
   Google Scholar
• Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs’ Action through miRNA Editing. Int J Mol Sci. 2019;20(24):6249.
   PubMed Web of Science ®Google Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12’23.
   PubMed Web of Science ®Google Scholar
• Lu T, Rothenberg M. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202’1207.
   PubMed Web of Science ®Google Scholar
• Li P, Tu M, Ho P, et al. In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. Theranostics. 2021;11(10):4858’4871.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hao W, Wang H. miR-557 suppressed the malignant behaviours of osteosarcoma cells by reducing HOXB9 and deactivating the EMT process. Artif Cells Nanomed Biotechnol. 2021;49(1):230’239.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu M, Bu J, et al. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. Life Sci. 2021;268:118925.
   PubMed Web of Science ®Google Scholar
• Gorur A, Bayraktar R, Ivan C, et al. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy - Nucleic Acids. 2021;23:930’943.
   Google Scholar
• Du Y, Yang H, Li Y, et al. Long non-coding RNA LINC01137 contributes to oral squamous cell carcinoma development and is negatively regulated by miR-22-3p. Cell Oncol (Dordr). 2021;44(3):595’609.
   Web of Science ®Google Scholar
• Tian Y, Guan Y, Su Y, et al. TRPM2-AS Promotes Bladder Cancer by Targeting miR-22-3p and Regulating GINS2 mRNA Expression. <![cdata[oncotargets and Therapy]]>. 2021;14:1219’1237.
   PubMed Web of Science ®Google Scholar
• Duchartre Y, Kim Y, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141’149.
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985’999.
   PubMed Web of Science ®Google Scholar
• Harb J, Lin P, Hao J. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics. Curr Oncol Rep. 2019;21(2):12.
   PubMed Web of Science ®Google Scholar
• Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5).
   Web of Science ®Google Scholar
• Wang J, Xie S, Liu J, et al. MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/β-catenin pathway. BMC Urol. 2021;21(1):40.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Q, Li J, et al. MicroRNA-15a-5p inhibits endometrial carcinoma proliferation, invasion and migration via downregulation of VEGFA and inhibition of the Wnt/β-catenin signaling pathway. Oncol Lett. 2021;21(4):310.
   PubMed Web of Science ®Google Scholar
• Cheng C, Li W, Peng X, et al. miR-1254 induced by NESG1 inactivates HDGF/DDX5-stimulated nuclear translocation of β-catenin and suppresses NPC metastasis. Molecular therapy. Molecular Therapy - Methods & Clinical Development. 2021;20:615’624.
   PubMed Web of Science ®Google Scholar
• Dang Y, Ouyang X, Ren W, et al. LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p. Cancer Manag Res. 2021;13:5163’5175.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu Q, Zhao J, et al. Long Noncoding RNA AATBC Promotes the Proliferation and Migration of Prostate Cancer Cell Through miR-1245b-5p/CASK Axis. Cancer Manag Res. 2021;13:5091’5100.
   PubMed Web of Science ®Google Scholar
• Zhou B, Ge Y, Shao Q, et al. Long noncoding RNA LINC00284 facilitates cell proliferation in papillary thyroid cancer via impairing miR-3127-5p targeted E2F7 suppression. Cell Death Discov. 2021;7(1):156.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang P, Zhang D, et al. LncRNA SNHG14 promotes cell proliferation and invasion in colorectal cancer through modulating miR-519b-3p/DDX5 axis. J Cancer. 2021;12(16):4958’4970.
   PubMed Web of Science ®Google Scholar
• Tortelote G, Reis R, de Almeida Mendes F, et al. Complexity of the Wnt/β‑catenin pathway: searching for an activation model. Cell Signal. 2017;40:30’43.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang J, Gao X, et al. Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2. J Cell Physiol. 2021;236(8):5757’5770.
   PubMed Web of Science ®Google Scholar
• Wu D, Jia H, Zhang Z, et al. Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the PI3K/AKT pathway. J Gene Med. 2021;23(2):e3300.
   PubMed Web of Science ®Google Scholar
• Wu Q, Ma J, Wei J, et al. lncRNA SNHG11 Promotes Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway and Oncogenic Autophagy. Mol Ther. 2021;29(3):1258’1278.
   PubMed Web of Science ®Google Scholar
• Cao T, Zhen X. Dysregulation of miRNA and its potential therapeutic application in schizophrenia. CNS Neurosci Ther. 2018;24(7):586’597.
   PubMed Web of Science ®Google Scholar
• Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Conti G. Environment and Neurodegenerative Diseases: an Update on miRNA Role. MicroRNA (Shariqah, United Arab Emirates). 2017;6(3):157’165
   PubMedGoogle Scholar
• Rupaimoole R, Slack F. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203’222.
   PubMed Web of Science ®Google Scholar
• Saccomani V, Grassi A, Piovan E, et al. miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia. Cells. 2020;9(7).
   Web of Science ®Google Scholar
• He W, Zhang Y, Xia S. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis. Thorac Cancer. 2020;11(3):549’560.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhan F, Li D, et al. RGMB-AS1/miR-22-3p/NFIB axis contributes to the progression of gastric cancer. Neoplasma. 2020;67(3):484’491.
   PubMed Web of Science ®Google Scholar
• Sha Q, Chen L, Xi J, et al. Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1057’1066.
   PubMed Web of Science ®Google Scholar
• Xiao J, Niu S, Zhu J, et al. miR‑22‑3p enhances multi‑chemoresistance by targeting NET1 in bladder cancer cells. Oncol Rep. 2018;39(6):2731’2740.
   PubMed Web of Science ®Google Scholar
• Han T, Hur K, Cho H, et al. Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma. Cancers (Basel). 2020;12(9).
   Web of Science ®Google Scholar
• Zhou X, Zhang W, Jin M, et al. lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis. 2017;8(7):e2929.
   PubMedGoogle Scholar
• Zeng Z, Xia L, Fan S, et al. Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to promote resolution of intimal hyperplasia Via TET2-mediated smooth muscle cell differentiation. Circulation. 2021;143(4):354’371.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang S, Chen Z, et al. CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1. Cell Death Dis. 2019;10(12):885.
   PubMedGoogle Scholar
• Malakar P, Stein I, Saragovi A, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-Mediated translation of TCF7L2. Cancer Res. 2019;79(10):2480’2493.
   PubMed Web of Science ®Google Scholar
• Zheng A, Song X, Zhang L, et al. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):305.
   PubMedGoogle Scholar
• Wenzel J, Rose K, Haghighi E, et al. Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells. Oncogene. 2020;39(19):3893’3909.
   PubMed Web of Science ®Google Scholar
• Bem J, Brożko N, Chakraborty C, et al. Wnt/β-catenin signaling in brain development and mental disorders keeping TCF7L2 in mind. FEBS Lett. 2019;593(13):1654’1674.
   PubMed Web of Science ®Google Scholar
• Li R, Ou J, Li L, et al. The Wnt signaling pathway effector TCF7L2 mediates olanzapine-Induced weight gain and insulin Resistance. Front Pharmacol. 2018;9:379.
   PubMed Web of Science ®Google Scholar
• Archbold HC, Yang YX, Chen L, et al. How do they do Wnt they do?: regulation of transcription by the Wnt/β-catenin pathway. [J].Acta Physiol (Oxf). 2012;204. 74’109.
   PubMed Web of Science ®Google Scholar
• Fei L, van Den Broek O, Destrée O, et al. Distinct roles for Xenopus Tcf/Lef genes in mediating specific responses to Wnt/β-catenin signalling in mesoderm development. [J].Development. 2005;132(24):5375’5385.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Virshup D. Wnt Signaling and Drug Resistance in Cancer. Mol Pharmacol. 2020;97(2):72’89.
   PubMed Web of Science ®Google Scholar
• Teeuwssen M, Fodde R. Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance. J Clin Med. 2019;8(10).
   Web of Science ®Google Scholar